About: Melinta Therapeutics

An Entity of Type: agent, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut. In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. It was renamed Melinta Therapeutics in 2013. On April 2020, it was transferred to affiliates of its creditor .

Property Value
dbo:abstract
  • Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut. In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. It was renamed Melinta Therapeutics in 2013. One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006, was approved by the FDA in 2017. As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne. Melinta shredded off its discovery research team in late 2018.It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019. On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection. On April 2020, it was transferred to affiliates of its creditor . (en)
dbo:foundingYear
  • 2000-01-01 (xsd:gYear)
dbo:industry
dbo:location
dbo:product
dbo:regionServed
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 19430636 (xsd:integer)
dbo:wikiPageLength
  • 4417 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1123406947 (xsd:integer)
dbo:wikiPageWikiLink
dbp:areaServed
  • Worldwide (en)
dbp:foundation
  • 2000 (xsd:integer)
dbp:homepage
dbp:industry
dbp:location
dbp:name
  • Melinta Therapeutics (en)
dbp:products
dbp:wikiPageUsesTemplate
dcterms:subject
georss:point
  • 40.80164 -74.4586
rdf:type
rdfs:comment
  • Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut. In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. It was renamed Melinta Therapeutics in 2013. On April 2020, it was transferred to affiliates of its creditor . (en)
rdfs:label
  • Melinta Therapeutics (en)
owl:sameAs
geo:geometry
  • POINT(-74.458602905273 40.801639556885)
geo:lat
  • 40.801640 (xsd:float)
geo:long
  • -74.458603 (xsd:float)
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Melinta Therapeutics (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License